Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity.
Lalama CM, Jennings C, Johnson VA, Coombs RW, McKinnon JE, Bremer JW, Cobb BR, Cloherty GA, Mellors JW, Ribaudo HJ; AIDS Clinical Trials Group. Lalama CM, et al. Among authors: johnson va. J Clin Microbiol. 2015 Aug;53(8):2659-66. doi: 10.1128/JCM.00801-15. Epub 2015 Jun 10. J Clin Microbiol. 2015. PMID: 26063861 Free PMC article.
Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter.
Demeter LM, Bosch RJ, Coombs RW, Fiscus S, Bremer J, Johnson VA, Erice A, Jackson JB, Spector SA, Squires KM, Fischl MA, Hughes MD, Hammer SM. Demeter LM, et al. Among authors: johnson va. J Clin Microbiol. 2002 Jun;40(6):2089-94. doi: 10.1128/JCM.40.6.2089-2094.2002. J Clin Microbiol. 2002. PMID: 12037070 Free PMC article. Clinical Trial.
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.
Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM, Frenkel LM, Hazelwood JD, Johnson VA, Kearney M, Kovacs A, Kuritzkes DR, Metzner KJ, Nissley DV, Nowicki M, Palmer S, Ziermann R, Zhao RY, Jennings CL, Bremer J, Brambilla D, Mellors JW. Halvas EK, et al. Among authors: johnson va. J Clin Microbiol. 2006 Jul;44(7):2612-4. doi: 10.1128/JCM.00449-06. J Clin Microbiol. 2006. PMID: 16825395 Free PMC article.
Accuracy of the TRUGENE HIV-1 genotyping kit.
Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd RM Jr, Reid C, Morgan GF, Winslow DL. Grant RM, et al. Among authors: johnson va. J Clin Microbiol. 2003 Apr;41(4):1586-93. doi: 10.1128/JCM.41.4.1586-1593.2003. J Clin Microbiol. 2003. PMID: 12682149 Free PMC article.
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.
Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM. Kuritzkes DR, et al. Among authors: johnson va. J Infect Dis. 2008 Mar 15;197(6):867-70. doi: 10.1086/528802. J Infect Dis. 2008. PMID: 18269317
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA 3rd, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team. Paredes R, et al. Among authors: johnson va. J Infect Dis. 2010 Mar;201(5):662-71. doi: 10.1086/650543. J Infect Dis. 2010. PMID: 20102271 Free PMC article.
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT. Hughes MD, et al. Among authors: johnson va. Ann Intern Med. 1997 Jun 15;126(12):929-38. doi: 10.7326/0003-4819-126-12-199706150-00001. Ann Intern Med. 1997. PMID: 9182469 Clinical Trial.
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.
Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS. Marschner IC, et al. Among authors: johnson va. J Infect Dis. 1998 Jan;177(1):40-7. doi: 10.1086/513823. J Infect Dis. 1998. PMID: 9419168 Clinical Trial.
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.
Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS. Welles SL, et al. Among authors: johnson va. J Infect Dis. 1996 Oct;174(4):696-703. doi: 10.1093/infdis/174.4.696. J Infect Dis. 1996. PMID: 8843205
154 results